Pediatric toxic epidermal necrolysis treated successfully with infliximab
Research output: Contribution to journal › Journal article › Research › peer-review
Successful management of toxic epidermal necrolysis (TEN) with tumor necrosis factor-α inhibitors has been described in adults. We present a case of a 7-year-old boy with infection-associated TEN, diagnosed by typical clinical and histopathological features, most likely caused by Mycoplasma pneumoniae. Treatment with a single dose of infliximab 5 mg/kg intravenously on day 5 after the onset of symptoms was followed by cessation of all blister formation over 3 days and complete resolution within a week. Sequelae were mild, consisting of postinflammatory hyperpigmentation and dry eyes.
Original language | English |
---|---|
Journal | Pediatric Dermatology |
Volume | 36 |
Issue number | 3 |
Pages (from-to) | 342-345 |
Number of pages | 4 |
ISSN | 0736-8046 |
DOIs | |
Publication status | Published - 2019 |
- infliximab, mycoplasma pneumoniae, Stevens-Johnson syndrome, toxic epidermal necrolysis, toxic epidermal necrolysis, alpha inhibitor
Research areas
ID: 226414562